Trade Summary

3 days ago, Rodman David Malcom, serving as Chief Medical Officer at Mineralys Therapeutics, Inc. (MLYS), sold 20,407 shares at $27.28 per share, for a total transaction value of $556,671.34. Following this transaction, Rodman David Malcom now holds 51,384 shares of MLYS.

This sale represents a 28.43% decrease in Rodman David Malcom's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, July 13, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, July 16, 2026 (accepted Jul 15, 8:58 PM ET), 3 days after the trade was made.

Mineralys Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.